Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Collegium Pharma (COLL)

Collegium Pharma (COLL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,238,249
  • Shares Outstanding, K 32,706
  • Annual Sales, $ 566,770 K
  • Annual Income, $ 48,160 K
  • 60-Month Beta 1.06
  • Price/Sales 2.20
  • Price/Cash Flow 3.46
  • Price/Book 6.22
Trade COLL with:

Options Overview Details

View History
  • Implied Volatility 48.66% ( -13.41%)
  • Historical Volatility 58.17%
  • IV Percentile 51%
  • IV Rank 51.05%
  • IV High 88.09% on 09/21/23
  • IV Low 7.53% on 06/14/23
  • Put/Call Vol Ratio 0.09
  • Today's Volume 59
  • Volume Avg (30-Day) 12
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 1,084
  • Open Int (30-Day) 1,077

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate 1.36
  • Number of Estimates 4
  • High Estimate 1.45
  • Low Estimate 1.25
  • Prior Year 1.18
  • Growth Rate Est. (year over year) +15.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.42 +3.55%
on 05/10/24
38.60 -18.39%
on 05/09/24
-6.49 (-17.08%)
since 04/10/24
3-Month
30.42 +3.55%
on 05/10/24
40.95 -23.08%
on 03/28/24
-1.98 (-5.91%)
since 02/09/24
52-Week
20.83 +51.22%
on 07/06/23
40.95 -23.08%
on 03/28/24
+8.41 (+36.42%)
since 05/10/23

Most Recent Stories

More News
Sweetgreen, Natera rise; Collegium Pharmaceutical, Akamai fall, 5/10/2024

Stocks that traded heavily or had substantial price changes on Friday: Sweetgreen, Natera rise; Collegium Pharmaceutical, Akamai fall

DBX : 23.13 (-0.04%)
PGNY : 27.53 (-15.29%)
NTRA : 105.29 (+10.19%)
MTD : 1,510.25 (+17.04%)
AKAM : 91.19 (-11.00%)
COLL : 31.50 (-16.80%)
Collegium Pharmaceutical: Q1 Earnings Snapshot

Collegium Pharmaceutical: Q1 Earnings Snapshot

COLL : 31.50 (-16.80%)
Collegium Pharmaceutical: Q4 Earnings Snapshot

Collegium Pharmaceutical: Q4 Earnings Snapshot

COLL : 31.50 (-16.80%)
Collegium Pharmaceutical: Q3 Earnings Snapshot

Collegium Pharmaceutical: Q3 Earnings Snapshot

COLL : 31.50 (-16.80%)
A Little Known Strategy Indicates These Three Companies Could Explode!

In this article, we look at price action strategies and uncover three companies with the potential for a breakout.

VSEC : 79.78 (-1.12%)
BAH : 156.06 (+1.11%)
COLL : 31.50 (-16.80%)
Collegium Pharmaceutical: Q2 Earnings Snapshot

Collegium Pharmaceutical: Q2 Earnings Snapshot

COLL : 31.50 (-16.80%)
Collegium Pharmaceutical (COLL) Reports Q1 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with...

COLL : 31.50 (-16.80%)
Collegium Pharmaceutical (COLL) Q1 Earnings Meet Estimates

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 0% and 4.07%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

COLL : 31.50 (-16.80%)
XBIO : 3.90 (-3.62%)
Collegium Pharmaceutical: Q1 Earnings Snapshot

Collegium Pharmaceutical: Q1 Earnings Snapshot

COLL : 31.50 (-16.80%)
Pacira (PCRX) Lags Q1 Earnings Estimates

Pacira (PCRX) delivered earnings and revenue surprises of -11.67% and 2.12%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

PCRX : 29.42 (-1.47%)
COLL : 31.50 (-16.80%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company's product candidate consists of COL-195, COL-196, COL-171,...

See More

Key Turning Points

3rd Resistance Point 37.11
2nd Resistance Point 35.55
1st Resistance Point 33.53
Last Price 31.50
1st Support Level 29.95
2nd Support Level 28.39
3rd Support Level 26.37

See More

52-Week High 40.95
Fibonacci 61.8% 33.26
Last Price 31.50
Fibonacci 50% 30.89
Fibonacci 38.2% 28.52
52-Week Low 20.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar